Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 5/20 | 0.61 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13919575 | 0.90 | ALDH1A1 (0.52) | NQO2L3MBTL1MAPTKDM4ETDP1 | |
| SCHEMBL28131200 | 0.89 | L3MBTL1 (0.50) | NQO2L3MBTL1MAPTKDM4ETDP1 | |
| SCHEMBL16833045 | 0.85 | ALDH1A1 (0.58) | NQO2GRM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL16832348 | 0.85 | NQO2 (0.60) | NQO2GRM2L3MBTL1KDM4EPLA2G2A | |
| SCHEMBL16832328 | 0.85 | PLA2G2A (0.64) | NQO2GRM2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL16832418 | 0.85 | NQO2 (0.60) | NQO2GRM2L3MBTL1MAPTKDM4E | |
| SCHEMBL16833047 | 0.85 | L3MBTL1 (0.67) | NQO2GRM2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL6605024 | 0.83 | KDM4E (0.65) | NQO2GRM2L3MBTL1MAPTKDM4E | |
| SCHEMBL28100426 | 0.83 | KDM4E (0.56) | L3MBTL1MAPTKDM4ETDP1MAPK1 | |
| SCHEMBL16832968 | 0.79 | NQO2 (0.66) | NQO2GRM2L3MBTL1KDM4EPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | disclosed |
| EP-3083598-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015091428-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | NQO2 338/4885GRM2 817/4885L3MBTL1 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.